By Michael Dabaie
Celgene Corp. (CELG) said the European Commission has approved two new triplet regimens based on Celgene's Revlimid and Imnovid.
Revlimid in combination with bortezomib and dexamethasone is now indicated for the treatment of adult patients with previously untreated multiple myeloma who aren't eligible for transplant.
Imnovid, in combination with bortezomib and dexamethasone, is now indicated for the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide, the company said.
The triplet regimens aren't approved for use in the U.S., Celgene said.
Write to Michael Dabaie at firstname.lastname@example.org